Utility of glucagon-like-peptide-1-receptor agonists in mast cell activation syndrome.
Afrin LB, Weinstock LB, Dempsey TT, Aschenbrenner K, Blitshteyn S, Schofield JR.
Am J Med Sci. 2025 Oct;370(4):377-382. doi: 10.1016/j.amjms.2025.07.006. Epub 2025 Jul 15.
Systemic mastocytosis: 2023 update on diagnosis and management in adults.
Costa A, Scalzulli E, Carmosino I, Capriata M, Ielo C, Masucci C, Passucci M, Martelli M, Breccia M.
Expert Opin Emerg Drugs. 2023 Dec;28(3):153-165. doi: 10.1080/14728214.2023.2221028. Epub 2023 Jun 6.
Generalized mastocytosis.
van Kammen E.
Acta Haematol. 1974;52(3):129-40. doi: 10.1159/000208232.
Neuropsychological features of adult mastocytosis.
Moura DS, Georgin-Lavialle S, Gaillard R, Hermine O.
Immunol Allergy Clin North Am. 2014 May;34(2):407-22. doi: 10.1016/j.iac.2014.02.001.
Mastocytosis and Anaphylaxis.
Schuch A, Brockow K.
Immunol Allergy Clin North Am. 2017 Feb;37(1):153-164. doi: 10.1016/j.iac.2016.08.017. Epub 2016 Oct 28.
Perioperative management of mastocytosis.
Lau S, Sprung J, Volcheck GW, Butterfield JH, Divekar RD, Weingarten TN.
J Anesth. 2023 Oct;37(5):741-748. doi: 10.1007/s00540-023-03228-x. Epub 2023 Jul 19.
Hymenoptera venom allergy in children.
Giovannini M, Mori F, Barni S, Saretta F, Arasi S, Castagnoli R, Liotti L, Mastrorilli C, Pecoraro L, Caminiti L, Sturm GJ, Marseglia GL, Del Giudice MM, Novembre E.
Ital J Pediatr. 2024 Dec 20;50(1):262. doi: 10.1186/s13052-024-01731-9.
Incontinentia pigmenti underlies thymic dysplasia, autoantibodies to type I IFNs, and viral diseases.
Rosain J, Le Voyer T, Liu X, Gervais A, Polivka L, Cederholm A, Berteloot L, Parent AV, Pescatore A, Spinosa E, Minic S, Kiszewski AE, Tsumura M, Thibault C, Esnaola Azcoiti M, Martinovic J, Philippot Q, Khan T, Marchal A, Charmeteau-De Muylder B, Bizien L, Deswarte C, Hadjem L, Fauvarque MO, Dorgham K, Eriksson D, Falcone EL, Puel M, Ünal S, Geraldo A, Le Floc'h C, Li H, Rheault S, Muti C, Bobrie-Moyrand C, Welfringer-Morin A, Fuleihan RL, Lévy R, Roelens M, Gao L, Materna M, Pellegrini S, Piemonti L, Catherinot E, Goffard JC, Fekkar A, Sacko-Sow A, Soudée C, Boucherit S, Neehus AL, Has C, Hübner S, Blanchard-Rohner G, Amador-Borrero B, Utsumi T, Taniguchi M, Tani H, Izawa K, Yasumi T, Kanai S, Migaud M, Aubart M, Lambert N, Gorochov G, Picard C, Soudais C, L'Honneur AS, Rozenberg F, Milner JD, Zhang SY, Vabres P, Trpinac D, Marr N, Boddaert N, Desguerre I, Pasparakis M, Miller CN, Poziomczyk CS, Abel L, Okada S, Jouanguy E, Cheynier R, Zhang Q, Cobat A, Béziat V, Boisson B, Steffann J, Fusco F, Ursini MV, Hadj-Rabia S, Bodemer C, Bustamante J, Luche H, Puel A, Courtois G, Bastard P, Landegren N, Anderson MS, Casanova JL.
J Exp Med. 2024 Nov 4;221(11):e20231152. doi: 10.1084/jem.20231152. Epub 2024 Oct 1.
Pseudoanaphylaxis.
Russell WJ, Smith WB.
Anaesth Intensive Care. 2006 Dec;34(6):801-3. doi: 10.1177/0310057X0603400618.
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial.
Gotlib J, Reiter A, Radia DH, Deininger MW, George TI, Panse J, Vannucchi AM, Platzbecker U, Alvarez-Twose I, Mital A, Hermine O, Dybedal I, Hexner EO, Hicks LK, Span L, Mesa R, Bose P, Pettit KM, Heaney ML, Oh ST, Sen J, Lin HM, Mar BG, DeAngelo DJ.
Nat Med. 2021 Dec;27(12):2192-2199. doi: 10.1038/s41591-021-01539-8. Epub 2021 Dec 6.
